A global, phase 3 clinical trial will investigate a novel drug in the post neoadjuvant setting that researchers hope will be a significant improvement over the current standard of care.
Researchers have identified quantitative features extracted from MRI images of HER2-positive breast tumors and the tumor environment that may provide cues to patients’ likelihood of response to targeted chemotherapy.
What research abstracts presented at this year’s American Society of Clinical Oncology annual meeting will have the biggest potential impact on clinical practice? Cleveland Clinic Cancer Center physicians make their picks.
A new option proves effective for patients with HER2+ early breast cancer with residual disease after neoadjuvant therapy.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Cleveland Clinic’s multidisciplinary approach to cancer care is demonstrated in the new Tumor Board webcast video series. The series launches with an HER2-positive breast cancer case.
A unique trial will test the combination of two powerful and targeted breast cancer drugs, determining their safety and tolerability in Phase I and the overall response rate in Phase II.